文献速递胃肠动力与功能性疾病

替加色罗治疗65岁以下无心血管疾病女性便秘型肠易激综合征:4项对照试验汇总分析

Tegaserod for Irritable Bowel Syndrome With Constipation in Women Younger Than 65 Years Without Cardiovascular Disease: Pooled Analyses of 4 Controlled Trials.
PubMed 文献 · Am J Gastroenterol · 2021-01-01

该汇总分析纳入4项12周随机安慰剂对照试验,评估替加色罗6 mg每日两次治疗便秘型肠易激综合征(IBS-C)的疗效。在全部女性和65岁以下无心血管缺血事件史的女性中,替加色罗组临床应答率均显著高于安慰剂组,不良事件相似,未观察到相关显著心血管事件。

要点

  • 替加色罗6 mg每日两次可显著改善IBS-C女性患者的症状缓解。
  • 在65岁以下无心血管缺血事件史的女性中,疗效同样显著且安全性良好。
  • 临床应答率在指示人群中替加色罗组为44.1%,安慰剂组为36.5%。

核心结论

  • 替加色罗6 mg每日两次可减轻全部女性和FDA指示人群(65岁以下无心血管缺血事件史女性)的IBS-C症状。

研究设计与样本

  • 汇总4项12周随机安慰剂对照试验,评估替加色罗6 mg每日两次治疗IBS-C。
  • 分析两组:全部女性(总体人群)和65岁以下无心血管缺血事件史女性(指示人群)。
  • 总体人群2939例(替加色罗1478例,安慰剂1461例),指示人群2752例(替加色罗1386例,安慰剂1366例)。

主要发现

  • 总体人群替加色罗 vs 安慰剂临床应答的汇总OR为1.37(95%CI 1.18-1.59;P<0.001)。
  • 指示人群替加色罗 vs 安慰剂临床应答的汇总OR为1.38(95%CI 1.18-1.61;P<0.001)。
  • 总体人群最后4周临床应答率:替加色罗43.3% vs 安慰剂35.9%(P<0.001)。
  • 指示人群最后4周临床应答率:替加色罗44.1% vs 安慰剂36.5%(P<0.001)。
  • 两组不良事件相似,≤1个心脏危险因素的患者中未观察到与替加色罗相关的显著心血管事件。

关键数值与推荐

  • 主要终点为IBS-C症状缓解的主观整体评估,应答定义为最后4周内≥50%时间「显著」或「完全」缓解,或100%时间至少「有些」缓解。

临床怎么用

  • 对于65岁以下无心血管缺血事件史的女性IBS-C患者,替加色罗6 mg每日两次可作为治疗选择。
  • 治疗前应评估心血管危险因素,≤1个心脏危险因素的患者未见相关显著心血管事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Tegaserod was the first US Food and Drug Administration-approved drug for irritable bowel syndrome with constipation (IBS-C) in women and was recently reapproved for use. Recognizing that clinical trials were performed almost 20 years ago, we performed an integrated analysis on patient-reported outcomes relevant to current practice including previously unpublished data. METHODS: Data from 4 12-week, randomized, placebo-controlled trials evaluating tegaserod 6 mg b.i.d. in patients with IBS-C were pooled. We analyzed 2 groups: all women (overall population) and women younger than 65 years without a history of cardiovascular ischemic events (indicated population). The primary end point was subjective global assessment of IBS-C symptom relief. Responders rated themselves as "considerably" or "completely" relieved ≥50% of the time or at least "somewhat relieved" 100% of the time over the last 4 weeks. RESULTS: The overall and indicated populations included 2,939 (tegaserod [n = 1,478]; placebo [n = 1,461]) and 2,752 (tegaserod [n = 1,386]; placebo [n = 1,366]) participants, respectively. The pooled odds ratios (95% confidence interval) for clinical response during the last 4 weeks in the overall and indicated populations with tegaserod were 1.37 (1.18, 1.59; P < 0.001) and 1.38 (1.18, 1.61; P < 0.001). In the overall and indicated populations, clinical response rates for tegaserod during the last 4 weeks were 43.3% and 44.1% versus 35.9% and 36.5% with placebo (P < 0.001). Adverse events were similar between groups. No significant cardiovascular events related to tegaserod were observed in patients with ≤1 cardiac risk factor. DISCUSSION: Tegaserod 6 mg b.i.d. reduced IBS-C symptoms in overall and US Food and Drug Administration-indicated populations (women aged <65 years with no history of cardiovascular ischemic events).

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Shah ED, Lacy BE, Chey WD, et al. Tegaserod for Irritable Bowel Syndrome With Constipation in Women Younger Than 65 Years Without Cardiovascular Disease: Pooled Analyses of 4 Controlled Trials. Am J Gastroenterol. 2021. PMID: 34047303. doi:10.14309/ajg.0000000000001313

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。